eGenesis is a biotechnology company which offers xenotransplantation technologies to patients with life-threatening conditions. This company was founded by George Church Ph.D and Luhan Yang Ph.D in 2015 and is headquartered in Cambridge, MA. eGenesis uses advanced gene-editing techniques, including CRISPR, to engineer animal organs intended for transplantation into human patients, aiming to provide a sustainable source of organs and tissues.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/04/2024 | Series D-1 | $100.04MM | $xx.xx | $332.59MM | Alta Partners, Arch Venture Partners, DaVita, Eisai Innovation, Farallon Capital Management, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Lux Capital, NATCO Pharmaceuticals, Parkwood | |
Price per Share
$xx.xx
Shares Outstanding
725,952,593
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alta Partners, Arch Venture Partners, DaVita, Eisai Innovation, Farallon Capital Management, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Lux Capital, NATCO Pharmaceuticals, Parkwood
|
||||||
09/04/2024 | Series D | $90.96MM | $xx.xx | $332.59MM | Alta Partners, Arch Venture Partners, DaVita, Eisai Innovation, Farallon Capital Management, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Lux Capital, NATCO Pharmaceuticals, Parkwood | |
Price per Share
$xx.xx
Shares Outstanding
461,979,343
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alta Partners, Arch Venture Partners, DaVita, Eisai Innovation, Farallon Capital Management, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Lux Capital, NATCO Pharmaceuticals, Parkwood
|
||||||
02/03/2021 | Series C-1 | $99.23MM | $xx.xx | $387.57MM | Alta Partners, Altium Capital, Arch Venture Partners, Catalio Capital Management, Farallon Capital Management, Fresenius Medical Care Ventures, Hbm Healthcare Investments, Invus, Irving Investors, Khosla Ventures, Leaps By Bayer, Lifesci Venture Partners, Monashee Investment Management, Osage University Partners, Polaris Partners, Samsara Biocapital, Symbiosis, Wellington Partners | |
Price per Share
$xx.xx
Shares Outstanding
50,860,191
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alta Partners, Altium Capital, Arch Venture Partners, Catalio Capital Management, Farallon Capital Management, Fresenius Medical Care Ventures, Hbm Healthcare Investments, Invus, Irving Investors, Khosla Ventures, Leaps By Bayer, Lifesci Venture Partners, Monashee Investment Management, Osage University Partners, Polaris Partners, Samsara Biocapital, Symbiosis, Wellington Partners
|
||||||
11/07/2019 | Series B-1 | $99.48MM | $xx.xx | $174.68MM | Alta Partners, Arch Venture Partners, Biomatics Capital, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Wellington Partners | |
Price per Share
$xx.xx
Shares Outstanding
55,111,122
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alta Partners, Arch Venture Partners, Biomatics Capital, Fresenius Medical Care Ventures, Khosla Ventures, Leaps By Bayer, Wellington Partners
|
||||||
03/16/2017 | Series A-1 | $39.15MM | $xx.xx | $56.52MM | Alexandria Venture Investments, Alta Partners, Arch Venture Partners, Berggruen Holdings North America, Biomatics Capital, Fan Ventures, Heritage Provider Network, Khosla Ventures, Uprising | |
Price per Share
$xx.xx
Shares Outstanding
27,375,893
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Alta Partners, Arch Venture Partners, Berggruen Holdings North America, Biomatics Capital, Fan Ventures, Heritage Provider Network, Khosla Ventures, Uprising
|